Tirzepatide

Tirzepatide activates two metabolic pathways—GIP and GLP-1—which may offer broader support for appetite control, metabolic regulation, and energy balance.
Exceptional Weight Loss
​Clinical trials show 15-22% average weight loss - more than any other medication
Heart Health BenefitsImproves cardiovascular health while managing diabetes effectively
FDA ApprovedLatest breakthrough technology approved for both diabetes and weight management
Why Choose Tirzepatide?Tirzepatide represents the latest breakthrough in weight management and diabetes treatment. As a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, it offers unprecedented results for patients seeking effective, long-term solutions.
Real Patient Success:"I lost 45 pounds in 6 months with Tirzepatide. My energy is back, my diabetes is under control, and I feel like myself again." - Sarah M.
Mechanism of Action

• GLP-1 Receptor Activation: Stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon release, and slows gastric emptying
• GIP Receptor Activation: Enhances insulin sensitivity and may have direct effects on fat metabolism
• Appetite Regulation: Acts on brain receptors to reduce appetite and food intake
• Gastric Motility: Slows gastric emptying, leading to increased satiety

Transformative Results
Diabetes Management:

• Significant reduction in HbA1c levels
• Improved glycemic control
• Low risk of hypoglycemia
• Cardiovascular benefits

Weight Management Success:

• Average weight loss of 15-22% in clinical trials
• Sustained weight reduction
• Improved body composition
• Reduction in waist circumference

Clinical Trial Highlights:In the SURMOUNT trials, patients achieved an average of 20.9% weight loss at the highest dose - results that exceeded all expectations and set new standards in weight management therapy.
Dosing and AdministrationRoute: Subcutaneous injection once weekly
Starting Dose: 2.5 mg once weekly for 4 weeks
Maintenance Doses:

• 5 mg once weekly (minimum effective dose)
• 7.5 mg once weekly
• 10 mg once weekly
• 12.5 mg once weekly
• 15 mg once weekly (maximum dose)

Injection Sites: Thigh, abdomen, or upper arm. Rotate injection sites weekly.
Side Effects
Common (≥5%):

• Nausea (12-18%)
• Diarrhea (12-16%)
• Vomiting (6-12%)
• Constipation (6-7%)
• Abdominal pain (6-9%)
• Injection site reactions

Serious (Rare):

• Pancreatitis
• Gallbladder disease
• Kidney problems
• Severe hypoglycemia (when combined with insulin/sulfonylureas)
• Thyroid C-cell tumors (theoretical risk)

Contraindications and Precautions
Contraindications:

• Personal or family history of medullary thyroid carcinoma
• Multiple Endocrine Neoplasia syndrome type 2
• Known hypersensitivity to tirzepatide

Use with Caution:

• History of pancreatitis
• Severe renal impairment
• Diabetic retinopathy
• Pregnancy and breastfeeding

​🔀 Tirzepatide Benefits (GLP-1 + GIP Receptor Agonist)Dual-incretin agonist approved for diabetes and weight management

• Enhanced weight loss – Clinical trials show greater weight reduction than semaglutide
• Improved insulin sensitivity – May help reduce insulin resistance
• Dual hormone action – Combines GLP-1 and GIP mechanisms for broader metabolic effects

• Blood glucose regulation – Helps manage A1c and fasting glucose in diabetics
• Appetite suppression – Strong satiety signaling via central nervous system
• Cardiometabolic markers – May improve blood pressure, cholesterol, and inflammation markers

🚫 Strong Contraindications (Do Not Use)
1. Personal or Family History of Medullary Thyroid Carcinoma (MTC)Black box warning: Like other GLP-1s, tirzepatide is contraindicated in patients with a personal or family history of MTC or MEN2.

2. Known Hypersensitivity to Tirzepatide or Its ComponentsAnaphylaxis and angioedema have been reported. Contraindicated in patients with known hypersensitivity.

3. PregnancyNot recommended during pregnancy. Must be discontinued at least 1–2 months before planned conception due to long half-life and unknown fetal risk.

4. History of PancreatitisUse is not recommended in patients with a history of pancreatitis. GLP-1 and GIP agonists may increase risk of recurrence.
⚠️ Use with Caution
1. Severe GI Disease (e.g., Gastroparesis)Tirzepatide significantly slows gastric emptying, which can worsen gastroparesis or cause intolerable nausea and bloating. Not recommended in patients with confirmed or suspected GI motility disorders.

2. Diabetic RetinopathyRapid improvement in glucose control may worsen existing retinopathy, as observed with other incretin-based therapies. Monitor closely in patients with eye disease.

3. Renal ImpairmentSevere vomiting, diarrhea, or dehydration can lead to acute kidney injury, particularly in older adults or those with existing renal compromise.

4. Gallbladder DiseaseTirzepatide increases risk of cholelithiasis (gallstones) due to weight loss and slowed GI motility. Monitor for RUQ pain.

5. BreastfeedingThere is no data on tirzepatide in breastfeeding. Avoid unless clearly indicated.
💉 Common Side Effects (Dose-Dependent)

• Nausea
• Vomiting
• Diarrhea or constipation
• Fatigue

• Injection site reactions
• Appetite suppression
• Dizziness or headache